Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

First international study to examine human developmental effects of environmental exposure to e-waste

A new international population study, led by the University of Cincinnati, will be the first to examine the human developmental effects of environmental exposure to the complex metal mixture found in electronic waste (e-waste).

20 Nov 2010

NEXTERONE Premixed Injection uses CyDex Captisol technology platform

CyDex Pharmaceuticals, Inc. today announced that Prism Pharmaceuticals' NEXTERONE (amiodarone HCL) Premixed Injection, which recently received supplemental new drug application (sNDA) approval from the U.S. Food and Drug Administration, makes use of the patent-protected CyDex Captisol technology platform.

20 Nov 2010

ProvenCare to focus on potential problems in lung cancer patients

Northwestern Memorial Hospital is one of six national participants in a pilot study that will test whether operable lung cancer patients and their families have a smoother care experience and better outcomes by hardwiring data systems to reduce medical error and to reliably adhere to best practice standards.

19 Nov 2010

3Sbio converts US$2.58 million debenture into Isotechnika Pharma

3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced that it has recently converted the remaining US$2.58 million of a US$4.5 million debenture convertible into Isotechnika Pharma Inc. ("Isotechnika") common shares issued on August 23, 2010.

19 Nov 2010

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.

19 Nov 2010

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new data at the MIT Center for Biomedical Innovation's Biomanufacturing Summit from its platform efforts aimed at developing RNAi technologies for applications in biologics manufacturing.

19 Nov 2010

CMOS processing compatible laser and 10Gb/s silicon modulator

CEA-Leti, coordinator of the European HELIOS project to accelerate commercialization of silicon photonics, said today project partners demonstrated a laser and a 10Gb/s silicon modulator using a process that is compatible with complementary metal-oxide semiconductor (CMOS) processing.

18 Nov 2010

Accentia and Biovest exit Chapter 11 as fully restructured organizations

Accentia Biopharmaceuticals, Inc. announced that, effective today, the Company and its majority-owned subsidiary, Biovest International, Inc., have both successfully completed their reorganizations. Pursuant to their respective Plans of Reorganization approved by the bankruptcy court, Accentia and Biovest have now formally exited Chapter 11 as fully restructured organizations.

18 Nov 2010

OmniVision commences mass production of OV6930 medical image sensor

OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions, today announced the initiation of mass production of the ultra-compact, high-performance OV6930. With a packaged footprint of only 1.8 x 1.8 mm, the OV6930 is the ideal solution for applications favoring a small profile.

18 Nov 2010

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced achievement of a US$4.0 million milestone payment from its development partner, Endo Pharmaceuticals Inc. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009.

18 Nov 2010

Pilot registry to identify AEDs in the community

Monday, Food and Drug Administration officials announced that the University of Colorado School of Medicine will work with the FDA to develop a pilot registry in Denver to identify AEDs in the community. This registry will link AEDs to emergency medical dispatch. It also could increase the ability of bystanders to save a life and help ensure that AEDs are located where they might be needed. Seattle and San Diego are the only other cities that will launch this effort.

17 Nov 2010

Health officials gather in Uruguay to discuss WHO anti-smoking treaty

"As sales to developing nations become ever more important to giant tobacco companies, they are stepping up efforts around the world to fight tough restrictions on the marketing of cigarettes," the New York Times reports in an article ahead of a conference in Punta del Este, Uruguay, which began on Monday. At the conference health officials are debating guidelines to enforce a global anti-smoking treaty known as the Framework Convention on Tobacco Control (FCTC) (Wilson, 11/13).

17 Nov 2010

UC San Diego researchers receive NIH grant to develop scaffolds

University of California, San Diego NanoEngineers won a grant from the National Institutes of Health (NIH) to develop the tools to manufacture biodegradable frames around which heart tissues functional blood vessels included will grow.

16 Nov 2010

FDA announces program to facilitate development of external defibrillators to treat abnormal heart rhythms

The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.

16 Nov 2010

Sonova 2010/11 first half sales increases 17.2% to CHF 832 million

Sonova generated a new sales record of CHF 832 million in the first half of 2010/11, an increase of 17.2% in Swiss francs compared to the previous year.

16 Nov 2010

Weikang third quarter revenue increases 55.2% to record $17.4 million

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced record fiscal 2010 third quarter results for period ended September 30, 2010.

15 Nov 2010

Protox decreases third quarter net and comprehensive loss to $1.6 million

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today released financial results for the third quarter, ended September 30, 2010.

15 Nov 2010

GenturaDx to showcase IDbox molecular diagnostic system at AMP 2010

GenturaDx will display its proprietary molecular diagnostic system, the IDbox System, at the annual meeting of the Association for Molecular Pathology (AMP) in San Jose, Calif. on November 17 – 20, 2010. The IDbox System incorporates all aspects of its proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette.

15 Nov 2010

Nutrastar third quarter revenues increase 81.2% to $6.46 million

Nutrastar International Inc., a leading producer and supplier of premium branded Traditional Chinese Medicine ("TCM") consumer products, today announced financial results for the three and nine months ended September 30, 2010.

15 Nov 2010

Science and precedent do not support biosimilar approach for plasma protein therapies

The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.

15 Nov 2010